Drug Target Review: Why PARP inhibitors fail: key role of the CST complex in BRCA1-deficient cancers (Sung)
April 8, 2026
Scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in collaboration with Dana-Farber Cancer Institute at Harvard Medical School, Columbia University and Irving Medical Center, have made a critical breakthrough in understanding why cancers with BRCA1 mutations become resistant to a widely used class of drugs known as PARP inhibitors - pharmacological inhibitors of poly [...]
